BMA Applauds Steps to Ensure No-Cost COVID-19 Vaccines in Medicare Advantage
Interim Final Rule ensures no cost sharing for Medicare beneficiaries
Washington, D.C. – Better Medicare Alliance (BMA), the leading research and advocacy organization supporting Medicare Advantage, responded to an Interim Final Rule from the Centers for Medicare & Medicaid Services (CMS) ensuring that any future COVID-19 vaccine receiving Food and Drug Administration (FDA) approval will be covered at no cost to Medicare Advantage or Traditional Fee-For-Service Medicare beneficiaries.
“The COVID-19 pandemic has wrought illness, death, stress, and loneliness on the Medicare population. As we look ahead to the hope of a safe and effective vaccine, relieving the worries about cost are critical,” said Allyson Y. Schwartz, President and CEO of the Better Medicare Alliance. “We appreciate the action taken by CMS to ensure that any future COVID-19 vaccine receiving FDA approval will be provided at zero cost to Medicare Advantage and Traditional Fee-For-Service Medicare beneficiaries. This welcome news will bring peace of mind to seniors as well as providers who are doing all they can to keep their patients safe and healthy in the midst of this ongoing pandemic.”